Hydrocortisone suspension and hydrocortisone tablets are not bioequivalent in the treatment of children with congenital adrenal hyperplasia

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 1, 2001, Pages 441-445

  Merke, D P ^a   Cho, D ^a   Calis, K A ^a   Keil, M F ^a   Chrousos, G P ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUDROCORTISONE; HYDROCORTISONE;

ADOLESCENT; APPETITE DISORDER; ARTICLE; BIOEQUIVALENCE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONGENITAL ADRENAL HYPERPLASIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG FORMULATION; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HYPERTENSION; MALE; MOOD; PRIORITY JOURNAL; SLEEP DISORDER; STEROID THERAPY; SUSPENSION; TABLET; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0035140327     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.86.1.7275     Document Type: Article

References (7)

1. New approaches to the treatment of congenital adrenal hyperplasia
2. Diagnosis and management of congenital adrenal hyperplasia
3. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency
4. Cortisol production rate in childhood and adolescence
5. Stability of hydrocortisone oral suspensions prepared from tablets and powder
6. Bioavailability of hydrocortisone from commercial 20-mg tablets
7. Plasma cortisol delivery from oral cortisol and cortisone acetate: Relative bioavailability